Literature DB >> 24493412

Impact of a predefined mediastinal ROI on inter-observer variability of planar ¹²³I-MIBG heart-to-mediastinum ratio.

Derk O Verschure1, Vivian Bongers, Petronella J Hagen, G Aernout Somsen, Berthe L F van Eck-Smit, Hein J Verberne.   

Abstract

AIM: Purpose of this study was to assess the impact of mediastinal region of interest (ROI) definition on intra- and inter-observer variability in relation to collimator type.
METHODS: Thirty-five subjects with CHF (80% men, mean age 66 ± 9 years, NYHA 2.4 ± 0.5, LVEF 29 ± 8.4%) were enrolled. 15 minutes and 4 hours post-injection (p.i.) of (123)I-MIBG, planar images were sequentially acquired with low energy high energy (LEHR) and medium energy (ME) collimators. In the first analysis, observer-defined mediastinal ROI was used. In the second analysis, a predefined mediastinal ROI was used. Intra- and inter-observer variability of late H/M was assessed using Lin's concordance coefficient (LCC).
RESULTS: There was substantial agreement between all three observers using predefined mediastinum ROI. LCCs for LEHR were 0.98, 0.96, and 0.95, for ME 0.98, 0.97, and 0.97. However, observer-defined mediastinal ROI resulted in poor-moderate agreement. LCCs for LEHR were 0.82, 0.94, and 0.70, for ME 0.77, 0.91, and 0.80. Intra-observer analysis using predefined mediastinal ROI showed substantial agreement. LCC was 0.97 for LEHR and 0.96 for ME.
CONCLUSION: Predefined mediastinal ROI results in low intra- and inter-observer variability of late H/M and is, therefore, to be preferred over observer-defined mediastinal ROI. Intra- and inter-observer variability of late H/M is not influenced by collimator choice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24493412     DOI: 10.1007/s12350-014-9854-z

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  18 in total

1.  Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy.

Authors:  P Merlet; C Benvenuti; D Moyse; F Pouillart; J L Dubois-Randé; A M Duval; D Loisance; A Castaigne; A Syrota
Journal:  J Nucl Med       Date:  1999-06       Impact factor: 10.057

2.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Authors:  John J V McMurray; Stamatis Adamopoulos; Stefan D Anker; Angelo Auricchio; Michael Böhm; Kenneth Dickstein; Volkmar Falk; Gerasimos Filippatos; Cândida Fonseca; Miguel Angel Gomez-Sanchez; Tiny Jaarsma; Lars Køber; Gregory Y H Lip; Aldo Pietro Maggioni; Alexander Parkhomenko; Burkert M Pieske; Bogdan A Popescu; Per K Rønnevik; Frans H Rutten; Juerg Schwitter; Petar Seferovic; Janina Stepinska; Pedro T Trindade; Adriaan A Voors; Faiez Zannad; Andreas Zeiher
Journal:  Eur Heart J       Date:  2012-05-19       Impact factor: 29.983

3.  I-123 MIBG cardiac uptake measurements: limitations of collimator choice and scatter correction in the clinical context.

Authors:  Alison M Fletcher; Duncan W Motherwell; Alexander D Small; Graham M McCurrach; Nicholas E R Goodfield; Mark C Petrie; William Martin; Stuart M Cobbe
Journal:  Nucl Med Commun       Date:  2010-07       Impact factor: 1.690

4.  Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion.

Authors:  Shunsuke Tamaki; Takahisa Yamada; Yuji Okuyama; Takashi Morita; Shoji Sanada; Yasumasa Tsukamoto; Masaharu Masuda; Keiji Okuda; Yusuke Iwasaki; Taku Yasui; Masatsugu Hori; Masatake Fukunami
Journal:  J Am Coll Cardiol       Date:  2009-02-03       Impact factor: 24.094

5.  Normal values and within-subject variability of cardiac I-123 MIBG scintigraphy in healthy individuals: implications for clinical studies.

Authors:  G Aernout Somsen; Hein J Verberne; Eric Fleury; Alberto Righetti
Journal:  J Nucl Cardiol       Date:  2004 Mar-Apr       Impact factor: 5.952

6.  Evidence for pre- to postsynaptic mismatch of the cardiac sympathetic nervous system in ischemic congestive heart failure.

Authors:  James H Caldwell; Jeanne M Link; Wayne C Levy; Jeanne E Poole; John R Stratton
Journal:  J Nucl Med       Date:  2008-01-16       Impact factor: 10.057

7.  Myocardial imaging in man with I-123 meta-iodobenzylguanidine.

Authors:  R C Kline; D P Swanson; D M Wieland; J H Thrall; M D Gross; B Pitt; W H Beierwaltes
Journal:  J Nucl Med       Date:  1981-02       Impact factor: 10.057

8.  Impact of mediastinal, liver and lung (123)I-metaiodobenzylguanidine ( (123)I-MIBG) washout on calculated (123)I-MIBG myocardial washout.

Authors:  Hein J Verberne; G Aernout Somsen; Pavol Povinec; Berthe L F van Eck-Smit; Arnold F Jacobson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-04       Impact factor: 9.236

9.  Reproducibility of planar (123)I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure.

Authors:  Caroline E Veltman; Mark J Boogers; Joris E Meinardi; Imad Al Younis; Petra Dibbets-Schneider; Ernst E Van der Wall; Jeroen J Bax; Arthur J H A Scholte
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-07-13       Impact factor: 9.236

10.  Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation.

Authors:  Hein J Verberne; Jan B A Habraken; Berthe L F van Eck-Smit; Denis Agostini; Arnold F Jacobson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-06       Impact factor: 9.236

View more
  6 in total

1.  Influence of ROI definition on the heart-to-mediastinum ratio in planar 123I-MIBG imaging.

Authors:  Christiane Klene; Christiane Jungen; Koichi Okuda; Yuske Kobayashi; Annabelle Helberg; Janos Mester; Christian Meyer; Kenichi Nakajima
Journal:  J Nucl Cardiol       Date:  2016-11-01       Impact factor: 5.952

Review 2.  Cardiac 123I-mIBG Imaging in Heart Failure.

Authors:  Derk O Verschure; Kenichi Nakajima; Hein J Verberne
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-25

Review 3.  Standardization of 123I-meta-iodobenzylguanidine myocardial sympathetic activity imaging: phantom calibration and clinical applications.

Authors:  Kenichi Nakajima; Derk O Verschure; Koichi Okuda; Hein J Verberne
Journal:  Clin Transl Imaging       Date:  2017-05-04

4.  A European myocardial 123I-mIBG cross-calibration phantom study.

Authors:  Derk O Verschure; Edwin Poel; Kenichi Nakajima; Koichi Okuda; Berthe L F van Eck-Smit; G Aernout Somsen; Hein J Verberne
Journal:  J Nucl Cardiol       Date:  2017-01-24       Impact factor: 5.952

5.  Role of cardiac 123I-mIBG imaging in predicting arrhythmic events in stable chronic heart failure patients with an ICD.

Authors:  Giuseppe De Vincentis; Viviana Frantellizzi; Francesco Fedele; Alessio Farcomeni; Paola Scarparo; Nicolò Salvi; Danilo Alunni Fegatelli; Massimo Mancone; Derk O Verschure; Hein J Verberne
Journal:  J Nucl Cardiol       Date:  2018-03-28       Impact factor: 5.952

Review 6.  Cardiac sympathetic activity in chronic heart failure: cardiac 123I-mIBG scintigraphy to improve patient selection for ICD implantation.

Authors:  D O Verschure; B L F van Eck-Smit; G A Somsen; R J J Knol; H J Verberne
Journal:  Neth Heart J       Date:  2016-12       Impact factor: 2.380

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.